CJC-1295 with DAC and Tesamorelin Interaction

Avoid
Researched 95% confidence

CJC-1295 with DAC and Tesamorelin have a potentially harmful interaction with 95% confidence. Both are GHRH analogs; no additional benefit and potential receptor competition. Both compounds affect the gi tract and pituitary, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..

Half-life: 6-8 days Typical dose: 1-2mg weekly growth hormone, weight loss
ghrh receptorigf1 carcinogenic riskestrogenicinsulin disrupting
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 with DAC, Tesamorelin). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (CJC-1295 with DAC, Tesamorelin). Monitor fasting glucose and HbA1c.

Frequently Asked Questions

Can I take CJC-1295 with DAC with Tesamorelin?

Combining CJC-1295 with DAC with Tesamorelin is not recommended. Both are GHRH analogs; no additional benefit and potential receptor competition.

Is CJC-1295 with DAC and Tesamorelin safe together?

This combination carries significant risk. Both are GHRH analogs; no additional benefit and potential receptor competition. Consult a healthcare professional before combining.

What are the interactions between CJC-1295 with DAC and Tesamorelin?

Both are GHRH analogs; no additional benefit and potential receptor competition. This assessment has 95% confidence and is based on documented research data.

How should I time CJC-1295 with DAC and Tesamorelin?

CJC-1295 with DAC has a half-life of 6-8 days and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 with DAC vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.